Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Markets and Markets to hold a virtual event » 09:46
06/25/20
06/25
09:46
06/25/20
09:46
ALLO

Allogene Therapeutics

$43.29 /

+ (+0.00%)

, CELG

Bought by BMY

$108.26 /

+ (+0.00%)

, MRK

Merck

$75.62 /

-0.22 (-0.29%)

, PFE

Pfizer

$32.09 /

-0.11 (-0.34%)

, QGEN

Qiagen

$43.07 /

+0.1 (+0.23%)

, REGN

Regeneron

$608.77 /

+3.675 (+0.61%)

, TAK

Takeda Pharmaceutical

$18.25 /

-0.08 (-0.44%)

Next-Gen 3rd Annual…

Next-Gen 3rd Annual Immuno-Oncology Virtual Congress will be held on June 25-26. Webcast Link

ShowHide Related Items >><<
TAK Takeda Pharmaceutical
$18.25 /

-0.08 (-0.44%)

REGN Regeneron
$608.77 /

+3.675 (+0.61%)

QGEN Qiagen
$43.07 /

+0.1 (+0.23%)

PFE Pfizer
$32.09 /

-0.11 (-0.34%)

MRK Merck
$75.62 /

-0.22 (-0.29%)

CELG Bought by BMY
$108.26 /

+ (+0.00%)

ALLO Allogene Therapeutics
$43.29 /

+ (+0.00%)

ALLO Allogene Therapeutics
$43.29 /

+ (+0.00%)

06/08/20 SunTrust
Allogene Therapeutics price target raised to $50 from $32 at SunTrust
06/01/20
Fly Intel: Top five analyst downgrades
06/01/20 Oppenheimer
Allogene Therapeutics price target raised to $55 from $50 at Oppenheimer
06/01/20 Raymond James
Allogene Therapeutics downgraded to Market Perform from Outperform at Raymond James
CELG Bought by BMY
$108.26 /

+ (+0.00%)

11/01/19 Standpoint Research
Celgene downgraded to Hold from Buy at Standpoint Research
11/01/19 Baird
Celgene downgraded to Neutral at Baird
11/01/19 Baird
Celgene downgraded d to Neutral from Outperform at Baird
09/23/19 Guggenheim
Agios Pharmaceuticals upgraded to Buy following selloff at Guggenheim
MRK Merck
$75.62 /

-0.22 (-0.29%)

06/25/20 Lake Street
Lake Street says Keytruda approval improves outlook for Checkpoint's cosibelimab
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/23/20 Morgan Stanley
Merck's COVID-19 antiviral candidate underappreciated, says Morgan Stanley
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
PFE Pfizer
$32.09 /

-0.11 (-0.34%)

06/22/20 Morgan Stanley
Morgan Stanley sees Eliquis patent being upheld, ruling being 'imminent'
06/16/20 SVB Leerink
SVB Leerink sees Pfizer as 'work in progress,' initiates with Market Perform
QGEN Qiagen
$43.07 /

+0.1 (+0.23%)

03/04/20 Stifel
Qiagen deal a positive for Thermo Fisher, says Stifel
03/04/20 Berenberg
Qiagen downgraded to Hold from Buy at Berenberg
03/03/20 Piper Sandler
Danaher unlikely to make competing bid for Qiagen, says Piper Sandler
02/05/20 Piper Sandler
Qiagen price target raised to $36 from $29 at Piper Sandler
REGN Regeneron
$608.77 /

+3.675 (+0.61%)

06/24/20 Credit Suisse
Regeneron price target raised to $700 from $605 at Credit Suisse
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
06/18/20 Piper Sandler
AbbVie atopic dermatitis data a postive, says Piper Sandler
06/15/20 Piper Sandler
Piper says 'meaningfully above-consensus estimates' for Dupixent are right
TAK Takeda Pharmaceutical
$18.25 /

-0.08 (-0.44%)

06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
TAK Takeda Pharmaceutical
$18.25 /

-0.08 (-0.44%)

REGN Regeneron
$608.77 /

+3.675 (+0.61%)

QGEN Qiagen
$43.07 /

+0.1 (+0.23%)

PFE Pfizer
$32.09 /

-0.11 (-0.34%)

MRK Merck
$75.62 /

-0.22 (-0.29%)

CELG Bought by BMY
$108.26 /

+ (+0.00%)

ALLO Allogene Therapeutics
$43.29 /

+ (+0.00%)

TAK Takeda Pharmaceutical
$18.25 /

-0.08 (-0.44%)

REGN Regeneron
$608.77 /

+3.675 (+0.61%)

QGEN Qiagen
$43.07 /

+0.1 (+0.23%)

PFE Pfizer
$32.09 /

-0.11 (-0.34%)

MRK Merck
$75.62 /

-0.22 (-0.29%)

TAK Takeda Pharmaceutical
$18.25 /

-0.08 (-0.44%)

REGN Regeneron
$608.77 /

+3.675 (+0.61%)

QGEN Qiagen
$43.07 /

+0.1 (+0.23%)

PFE Pfizer
$32.09 /

-0.11 (-0.34%)

MRK Merck
$75.62 /

-0.22 (-0.29%)

ALLO Allogene Therapeutics
$43.29 /

+ (+0.00%)

TAK Takeda Pharmaceutical
$18.25 /

-0.08 (-0.44%)

REGN Regeneron
$608.77 /

+3.675 (+0.61%)

QGEN Qiagen
$43.07 /

+0.1 (+0.23%)

PFE Pfizer
$32.09 /

-0.11 (-0.34%)

MRK Merck
$75.62 /

-0.22 (-0.29%)

Over a quarter ago
Conference/Events
The ASTCT and CIBMTR to hold a joint meeting » 04:55
02/23/20
02/23
04:55
02/23/20
04:55
ABBV

AbbVie

$94.96 /

+0.7 (+0.74%)

, ADPT

Adaptive Biotechnologies

$34.19 /

+0.37 (+1.09%)

, AMGN

Amgen

$222.80 /

+0.62 (+0.28%)

, ATNM

Actinium Pharmaceuticals

$0.26 /

+0.0088 (+3.50%)

, ATRA

Atara Biotherapeutics

$13.18 /

-0.34 (-2.51%)

, AZN

AstraZeneca

$50.17 /

+1.2 (+2.45%)

, BLUE

Bluebird Bio

$80.15 /

-2.38 (-2.88%)

, CDNA

CareDx

$28.25 /

+0.13 (+0.46%)

, CDTX

Cidara Therapeutics

$3.16 /

+ (+0.00%)

, CELG

Bought by BMY

$0.00 /

+ (+0.00%)

, EQ

Equillium

$5.48 /

+0.38 (+7.45%)

, GMDA

Gamida Cell

$4.55 /

-0.2 (-4.21%)

, GSK

GlaxoSmithKline

$43.11 /

+0.35 (+0.82%)

, HUM

Humana

$369.65 /

-1.9 (-0.51%)

, INCY

Incyte

$80.89 /

-1.88 (-2.27%)

, JAZ

Jazz Technologies

$0.00 /

+ (+0.00%)

, KDMN

Kadmon

$5.08 /

+0.03 (+0.59%)

, MGTA

Magenta Therapeutics

$14.00 /

-0.02 (-0.14%)

, MRK

Merck

$82.34 /

-0.14 (-0.17%)

, NVS

Novartis

$96.75 /

+0.44 (+0.46%)

, PFE

Pfizer

$35.71 /

-0.13 (-0.36%)

, RCKT

Rocket Pharmaceuticals

$22.73 /

-1.01 (-4.25%)

, SGEN

Seattle Genetics

$117.00 /

-1.3 (-1.10%)

, SNY

Sanofi

$50.83 /

+0.07 (+0.14%)

, TAK

Takeda Pharmaceutical

$18.78 /

+0.195 (+1.05%)

American Society for…

American Society for Transplantation & Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) hold the 2020 TCT: Transplantation & Cellular Therapy Meeting will be held in Orlando on February 19-23.

ShowHide Related Items >><<
ABBV AbbVie
$94.96 /

+0.7 (+0.74%)

02/18/20 Cowen
AbbVie price target raised to $105 from $98 at Cowen
02/14/20 Piper Sandler
Piper says Ubrelvy prescription trajectory bodes well for Biohaven's rimegepant
02/11/20 SunTrust
Allergan price target raised to $202 from $194 at SunTrust
02/10/20 Mizuho
AbbVie price target raised to $104 from $96 at Mizuho
ADPT Adaptive Biotechnologies
$34.19 /

+0.37 (+1.09%)

01/09/20 JPMorgan
Danaher, Thermo named JPMorgan's top 2020 picks in Life Science Tools
11/13/19 JPMorgan
Adaptive Biotechnologies still has upside potential despite rally, says JPMorgan
07/23/19
Fly Intel: Top five analyst initiations
07/23/19 BTIG
Adaptive Biotechnologies initiated with a Buy at BTIG
AMGN Amgen
$222.80 /

+0.62 (+0.28%)

02/14/20
Vertex remains top large-cap biotech pick at Citi
02/06/20 Argus
Amgen trading at attractive valuation, says Argus
02/03/20 SunTrust
Amgen price target lowered to $254 from $265 at SunTrust
01/31/20
Fly Intel: Top five analyst downgrades
ATNM Actinium Pharmaceuticals
$0.26 /

+0.0088 (+3.50%)

08/08/19 William Blair
Actinium Pharmaceuticals initiated with an Outperform at William Blair
ATRA Atara Biotherapeutics
$13.18 /

-0.34 (-2.51%)

11/08/19 JPMorgan
Atara Biotherapeutics downgraded to on lack of catalysts at JPMorgan
11/08/19 JPMorgan
Atara Biotherapeutics downgraded to Neutral from Overweight at JPMorgan
10/25/19 Stifel
Stifel recommend buying into weakness on Atara Biotherapeutics CSO resignation
10/25/19 Mizuho
Mizuho says CSO Chris Haqq to remain on as Atara adviser
AZN AstraZeneca
$50.17 /

+1.2 (+2.45%)

01/27/20 William Blair
PhaseBio could see increase to PB2452 addressable market, says William Blair
01/22/20 Liberum
Sanofi downgraded to Hold from Buy at Liberum (earlier)
01/22/20 Oppenheimer
Amarin price target raised to $13 from $8 at Oppenheimer
01/13/20 Roth Capital
Amarin's Vascepa now the 'go-to' after competitor failures, says Roth Capital
BLUE Bluebird Bio
$80.15 /

-2.38 (-2.88%)

02/20/20 Oppenheimer
Bluebird Bio price target lowered to $128 from $135 at Oppenheimer
02/19/20 Raymond James
Bluebird Bio downgraded to Market Perform from Strong Buy at Raymond James
02/19/20 Piper Sandler
Bluebird pushed Biologics License Application to second half, says Piper Sandler
02/03/20 Evercore ISI
Bluebird Bio upgraded to Outperform on undervalued assets at Evercore ISI
CDNA CareDx
$28.25 /

+0.13 (+0.46%)

01/27/20 Piper Sandler
CareDx gained first private payer decision for AlloSure, says Piper Sandler
12/19/19 Craig-Hallum
Natera kidney test to be covered under Medicare in February, says Craig-Hallum
12/19/19 Piper Sandler
CareDx should be bought on weakness from Natera coverage, says Piper
11/01/19 Piper Sandler
CareDx continues to build 'moat around transplant,' says Piper Jaffray
CDTX Cidara Therapeutics
$3.16 /

+ (+0.00%)

01/27/20 Cantor Fitzgerald
Street underappreciates Cidara's Cloudbreak AVCs, says Cantor Fitzgerald
12/04/19 WBB Securities
Cidara Therapeutics upgraded to Buy from Speculative Buy at WBB Securities
09/04/19 BTIG
Cidara Therapeutics price target lowered to $7 from $20 at BTIG
09/04/19
Cidara Therapeutics upgraded to Outperform after partnership at Wedbush
CELG Bought by BMY
$0.00 /

+ (+0.00%)

11/01/19 Standpoint Research
Celgene downgraded to Hold from Buy at Standpoint Research
11/01/19 Baird
Celgene downgraded to Neutral at Baird
11/01/19 Baird
Celgene downgraded d to Neutral from Outperform at Baird
09/23/19 Guggenheim
Agios Pharmaceuticals upgraded to Buy following selloff at Guggenheim
EQ Equillium
$5.48 /

+0.38 (+7.45%)

01/03/20 Stifel
Stifel says Incyte setback means Equillium may have most advanced aGVHD product
07/02/19 H.C. Wainwright
Equillium initiated with a Buy at H.C. Wainwright
GMDA Gamida Cell
$4.55 /

-0.2 (-4.21%)

09/20/19 JMP Securities
Gamida Cell initiated with an Outperform at JMP Securities
GSK GlaxoSmithKline
$43.11 /

+0.35 (+0.82%)

01/16/20 Barclays
GlaxoSmithKline downgraded to Underweight from Equal Weight at Barclays
12/16/19 Goldman Sachs
BioMarin, Regeneron among Goldman's six Healthcare 'laggards' for 2020
12/03/19 Morgan Stanley
Morgan Stanley sees high odds of Bluebird trading up after multiple myeloma data
12/02/19 SVB Leerink
GlaxoSmithKline initiated with an Outperform at SVB Leerink
HUM Humana
$369.65 /

-1.9 (-0.51%)

02/20/20 Stephens
Stephens watching near-term MCO stock reactions after Bloomberg's 'rough' debate
02/18/20 Deutsche Bank
Deutsche raises price targets in Managed Care on fading political risks
01/23/20 UBS
Humana price target raised to $406 from $321 at UBS
01/08/20 Credit Suisse
Humana price target raised to $400 from $378 at Credit Suisse
INCY Incyte
$80.89 /

-1.88 (-2.27%)

02/19/20 Piper Sandler
Incyte data on topical ruxolitinib 'impressive,' says Piper Sandler
02/19/20 Nomura Instinet
Incyte price target raised to $116 from $111 at Nomura Instinet
02/13/20 Piper Sandler
Piper Sandler says Incyte's Jakafi, 2020 launches are 'underappreciated'
02/04/20 BofA
Incyte reinstated with a Neutral at BofA
JAZ Jazz Technologies
$0.00 /

+ (+0.00%)

KDMN Kadmon
$5.08 /

+0.03 (+0.59%)

01/10/20 Nomura Instinet
Kadmon initiated with a Buy at Nomura Instinet
01/03/20 Cantor Fitzgerald
Incyte setback supports GVHD opportunity for Kadmon, says Cantor Fitzgerald
11/12/19 Cantor Fitzgerald
Kadmon price target raised to $10 from $8 at Cantor Fitzgerald
09/06/19 Cantor Fitzgerald
Cantor starts 'under-the-radar' Kadmon with Overweight rating
MGTA Magenta Therapeutics
$14.00 /

-0.02 (-0.14%)

01/15/20 BTIG
BTIG sees 'no real reason' for Magenta Therapeutics sell-off
12/06/19 BTIG
Magenta Therapeutics initiated with a Buy at BTIG
12/06/19 Goldman Sachs
Magenta Therapeutics assumed with a Neutral at Goldman Sachs
03/25/19 Goldman Sachs
Magenta Therapeutics downgraded to Neutral on valuation at Goldman Sachs
MRK Merck
$82.34 /

-0.14 (-0.17%)

02/19/20 Spin-Off Research
Merck initiated with a Buy at Spin-Off Research
02/14/20 SunTrust
Pfenex initiated with a Buy at SunTrust
02/06/20 RBC Capital
Merck price target lowered to $92 from $99 at RBC Capital
02/06/20 Maxim
Armata Pharmaceuticals initiated with a Buy at Maxim
NVS Novartis
$96.75 /

+0.44 (+0.46%)

02/17/20 Citi
Novartis downgraded to Neutral from Buy at Citi
02/03/20 Oppenheimer
Eyenovia downgraded to Perform from Outperform at Oppenheimer
01/06/20 JPMorgan
JPMorgan upgrades Sanofi to Overweight on 'unjustified' valuation gap
PFE Pfizer
$35.71 /

-0.13 (-0.36%)

02/12/20 Baird
Exact Sciences weakness would be buying opportunity, says Baird
02/11/20 Roth Capital
GlycoMimetics termination notice from Pfizer no surprise, says Roth Capital
02/06/20 Mizuho
Pfizer initiated with a Buy, $42 price target at Mizuho
02/05/20 Mizuho
Pfizer initiated with a Buy at Mizuho
RCKT Rocket Pharmaceuticals
$22.73 /

-1.01 (-4.25%)

12/09/19 Oppenheimer
Rocket Pharmaceuticals price target raised to $42 from $36 at Oppenheimer
12/06/19 Baird
Rocket Pharmaceuticals elevated to Fresh Pick, target raised to $41 at Baird
11/18/19 Piper Sandler
Rocket may be next leading lentiviral vector company, says Piper Jaffray
11/07/19 Piper Sandler
Rocket Pharmaceuticals data by year-end to boost shares, says Piper Jaffray
SGEN Seattle Genetics
$117.00 /

-1.3 (-1.10%)

02/18/20 Barclays
Seattle Genetics downgraded to Equal Weight from Overweight at Barclays
02/18/20 Barclays
Seattle Genetics downgraded to Equal Weight from Overweight at Barclays
02/12/20 H.C. Wainwright
Seattle Genetics price target raised to $150 from $140 at H.C. Wainwright
02/11/20 Goldman Sachs
Goldman boosts Seattle Genetics target to $165, sees attractive setup
SNY Sanofi
$50.83 /

+0.07 (+0.14%)

02/11/20
Fly Intel: Top five analyst initiations
02/11/20 SVB Leerink
Sanofi initiated with a Market Perform at SVB Leerink
02/06/20 H.C. Wainwright
Principia Biopharma price target raised to $70 from $62 at H.C. Wainwright
01/26/20 Goldman Sachs
Denali Therapeutics upgraded to Buy from Neutral at Goldman Sachs
TAK Takeda Pharmaceutical
$18.78 /

+0.195 (+1.05%)

02/12/20 Wells Fargo
Fate Therapeutics price target raised to $34 from $24 at Wells Fargo
11/19/19 Needham
Phathom Pharmaceuticals initiated with a Buy at Needham
11/01/19 Cowen
Takeda Pharmaceutical initiated with a Market Perform at Cowen
09/24/19 Jefferies
Takeda Pharmaceutical initiated with a Buy at Jefferies
Conference/Events
The ASTCT and CIBMTR to hold a joint meeting » 04:55
02/22/20
02/22
04:55
02/22/20
04:55
ABBV

AbbVie

$94.96 /

+0.7 (+0.74%)

, ADPT

Adaptive Biotechnologies

$34.19 /

+0.37 (+1.09%)

, AMGN

Amgen

$222.80 /

+0.62 (+0.28%)

, ATNM

Actinium Pharmaceuticals

$0.26 /

+0.0088 (+3.50%)

, ATRA

Atara Biotherapeutics

$13.18 /

-0.34 (-2.51%)

, AZN

AstraZeneca

$50.17 /

+1.2 (+2.45%)

, BLUE

Bluebird Bio

$80.15 /

-2.38 (-2.88%)

, CDNA

CareDx

$28.25 /

+0.13 (+0.46%)

, CDTX

Cidara Therapeutics

$3.16 /

+ (+0.00%)

, CELG

Bought by BMY

$0.00 /

+ (+0.00%)

, EQ

Equillium

$5.48 /

+0.38 (+7.45%)

, GMDA

Gamida Cell

$4.55 /

-0.2 (-4.21%)

, GSK

GlaxoSmithKline

$43.11 /

+0.35 (+0.82%)

, HUM

Humana

$369.65 /

-1.9 (-0.51%)

, INCY

Incyte

$80.89 /

-1.88 (-2.27%)

, JAZ

Jazz Technologies

$0.00 /

+ (+0.00%)

, KDMN

Kadmon

$5.08 /

+0.03 (+0.59%)

, MGTA

Magenta Therapeutics

$14.00 /

-0.02 (-0.14%)

, MRK

Merck

$82.34 /

-0.14 (-0.17%)

, NVS

Novartis

$96.75 /

+0.44 (+0.46%)

, PFE

Pfizer

$35.71 /

-0.13 (-0.36%)

, RCKT

Rocket Pharmaceuticals

$22.73 /

-1.01 (-4.25%)

, SGEN

Seattle Genetics

$117.00 /

-1.3 (-1.10%)

, SNY

Sanofi

$50.83 /

+0.07 (+0.14%)

, TAK

Takeda Pharmaceutical

$18.78 /

+0.195 (+1.05%)

American Society for…

American Society for Transplantation & Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) hold the 2020 TCT: Transplantation & Cellular Therapy Meeting will be held in Orlando on February 19-23.

ShowHide Related Items >><<
ABBV AbbVie
$94.96 /

+0.7 (+0.74%)

02/18/20 Cowen
AbbVie price target raised to $105 from $98 at Cowen
02/14/20 Piper Sandler
Piper says Ubrelvy prescription trajectory bodes well for Biohaven's rimegepant
02/11/20 SunTrust
Allergan price target raised to $202 from $194 at SunTrust
02/10/20 Mizuho
AbbVie price target raised to $104 from $96 at Mizuho
ADPT Adaptive Biotechnologies
$34.19 /

+0.37 (+1.09%)

01/09/20 JPMorgan
Danaher, Thermo named JPMorgan's top 2020 picks in Life Science Tools
11/13/19 JPMorgan
Adaptive Biotechnologies still has upside potential despite rally, says JPMorgan
07/23/19
Fly Intel: Top five analyst initiations
07/23/19 BTIG
Adaptive Biotechnologies initiated with a Buy at BTIG
AMGN Amgen
$222.80 /

+0.62 (+0.28%)

02/14/20
Vertex remains top large-cap biotech pick at Citi
02/06/20 Argus
Amgen trading at attractive valuation, says Argus
02/03/20 SunTrust
Amgen price target lowered to $254 from $265 at SunTrust
01/31/20
Fly Intel: Top five analyst downgrades
ATNM Actinium Pharmaceuticals
$0.26 /

+0.0088 (+3.50%)

08/08/19 William Blair
Actinium Pharmaceuticals initiated with an Outperform at William Blair
ATRA Atara Biotherapeutics
$13.18 /

-0.34 (-2.51%)

11/08/19 JPMorgan
Atara Biotherapeutics downgraded to on lack of catalysts at JPMorgan
11/08/19 JPMorgan
Atara Biotherapeutics downgraded to Neutral from Overweight at JPMorgan
10/25/19 Stifel
Stifel recommend buying into weakness on Atara Biotherapeutics CSO resignation
10/25/19 Mizuho
Mizuho says CSO Chris Haqq to remain on as Atara adviser
AZN AstraZeneca
$50.17 /

+1.2 (+2.45%)

01/27/20 William Blair
PhaseBio could see increase to PB2452 addressable market, says William Blair
01/22/20 Liberum
Sanofi downgraded to Hold from Buy at Liberum (earlier)
01/22/20 Oppenheimer
Amarin price target raised to $13 from $8 at Oppenheimer
01/13/20 Roth Capital
Amarin's Vascepa now the 'go-to' after competitor failures, says Roth Capital
BLUE Bluebird Bio
$80.15 /

-2.38 (-2.88%)

02/20/20 Oppenheimer
Bluebird Bio price target lowered to $128 from $135 at Oppenheimer
02/19/20 Raymond James
Bluebird Bio downgraded to Market Perform from Strong Buy at Raymond James
02/19/20 Piper Sandler
Bluebird pushed Biologics License Application to second half, says Piper Sandler
02/03/20 Evercore ISI
Bluebird Bio upgraded to Outperform on undervalued assets at Evercore ISI
CDNA CareDx
$28.25 /

+0.13 (+0.46%)

01/27/20 Piper Sandler
CareDx gained first private payer decision for AlloSure, says Piper Sandler
12/19/19 Craig-Hallum
Natera kidney test to be covered under Medicare in February, says Craig-Hallum
12/19/19 Piper Sandler
CareDx should be bought on weakness from Natera coverage, says Piper
11/01/19 Piper Sandler
CareDx continues to build 'moat around transplant,' says Piper Jaffray
CDTX Cidara Therapeutics
$3.16 /

+ (+0.00%)

01/27/20 Cantor Fitzgerald
Street underappreciates Cidara's Cloudbreak AVCs, says Cantor Fitzgerald
12/04/19 WBB Securities
Cidara Therapeutics upgraded to Buy from Speculative Buy at WBB Securities
09/04/19 BTIG
Cidara Therapeutics price target lowered to $7 from $20 at BTIG
09/04/19
Cidara Therapeutics upgraded to Outperform after partnership at Wedbush
CELG Bought by BMY
$0.00 /

+ (+0.00%)

11/01/19 Standpoint Research
Celgene downgraded to Hold from Buy at Standpoint Research
11/01/19 Baird
Celgene downgraded to Neutral at Baird
11/01/19 Baird
Celgene downgraded d to Neutral from Outperform at Baird
09/23/19 Guggenheim
Agios Pharmaceuticals upgraded to Buy following selloff at Guggenheim
EQ Equillium
$5.48 /

+0.38 (+7.45%)

01/03/20 Stifel
Stifel says Incyte setback means Equillium may have most advanced aGVHD product
07/02/19 H.C. Wainwright
Equillium initiated with a Buy at H.C. Wainwright
02/22/19 SVB Leerink
Equillium initiated with an Outperform at SVB Leerink
GMDA Gamida Cell
$4.55 /

-0.2 (-4.21%)

09/20/19 JMP Securities
Gamida Cell initiated with an Outperform at JMP Securities
GSK GlaxoSmithKline
$43.11 /

+0.35 (+0.82%)

01/16/20 Barclays
GlaxoSmithKline downgraded to Underweight from Equal Weight at Barclays
12/16/19 Goldman Sachs
BioMarin, Regeneron among Goldman's six Healthcare 'laggards' for 2020
12/03/19 Morgan Stanley
Morgan Stanley sees high odds of Bluebird trading up after multiple myeloma data
12/02/19 SVB Leerink
GlaxoSmithKline initiated with an Outperform at SVB Leerink
HUM Humana
$369.65 /

-1.9 (-0.51%)

02/20/20 Stephens
Stephens watching near-term MCO stock reactions after Bloomberg's 'rough' debate
02/18/20 Deutsche Bank
Deutsche raises price targets in Managed Care on fading political risks
01/23/20 UBS
Humana price target raised to $406 from $321 at UBS
01/08/20 Credit Suisse
Humana price target raised to $400 from $378 at Credit Suisse
INCY Incyte
$80.89 /

-1.88 (-2.27%)

02/19/20 Piper Sandler
Incyte data on topical ruxolitinib 'impressive,' says Piper Sandler
02/19/20 Nomura Instinet
Incyte price target raised to $116 from $111 at Nomura Instinet
02/13/20 Piper Sandler
Piper Sandler says Incyte's Jakafi, 2020 launches are 'underappreciated'
02/04/20 BofA
Incyte reinstated with a Neutral at BofA
JAZ Jazz Technologies
$0.00 /

+ (+0.00%)

KDMN Kadmon
$5.08 /

+0.03 (+0.59%)

01/10/20 Nomura Instinet
Kadmon initiated with a Buy at Nomura Instinet
01/03/20 Cantor Fitzgerald
Incyte setback supports GVHD opportunity for Kadmon, says Cantor Fitzgerald
11/12/19 Cantor Fitzgerald
Kadmon price target raised to $10 from $8 at Cantor Fitzgerald
09/06/19 Cantor Fitzgerald
Cantor starts 'under-the-radar' Kadmon with Overweight rating
MGTA Magenta Therapeutics
$14.00 /

-0.02 (-0.14%)

01/15/20 BTIG
BTIG sees 'no real reason' for Magenta Therapeutics sell-off
12/06/19 BTIG
Magenta Therapeutics initiated with a Buy at BTIG
12/06/19 Goldman Sachs
Magenta Therapeutics assumed with a Neutral at Goldman Sachs
03/25/19 Goldman Sachs
Magenta Therapeutics downgraded to Neutral on valuation at Goldman Sachs
MRK Merck
$82.34 /

-0.14 (-0.17%)

02/19/20 Spin-Off Research
Merck initiated with a Buy at Spin-Off Research
02/14/20 SunTrust
Pfenex initiated with a Buy at SunTrust
02/06/20 RBC Capital
Merck price target lowered to $92 from $99 at RBC Capital
02/06/20 Maxim
Armata Pharmaceuticals initiated with a Buy at Maxim
NVS Novartis
$96.75 /

+0.44 (+0.46%)

02/17/20 Citi
Novartis downgraded to Neutral from Buy at Citi
02/03/20 Oppenheimer
Eyenovia downgraded to Perform from Outperform at Oppenheimer
01/06/20 JPMorgan
JPMorgan upgrades Sanofi to Overweight on 'unjustified' valuation gap
PFE Pfizer
$35.71 /

-0.13 (-0.36%)

02/12/20 Baird
Exact Sciences weakness would be buying opportunity, says Baird
02/11/20 Roth Capital
GlycoMimetics termination notice from Pfizer no surprise, says Roth Capital
02/06/20 Mizuho
Pfizer initiated with a Buy, $42 price target at Mizuho
02/05/20 Mizuho
Pfizer initiated with a Buy at Mizuho
RCKT Rocket Pharmaceuticals
$22.73 /

-1.01 (-4.25%)

12/09/19 Oppenheimer
Rocket Pharmaceuticals price target raised to $42 from $36 at Oppenheimer
12/06/19 Baird
Rocket Pharmaceuticals elevated to Fresh Pick, target raised to $41 at Baird
11/18/19 Piper Sandler
Rocket may be next leading lentiviral vector company, says Piper Jaffray
11/07/19 Piper Sandler
Rocket Pharmaceuticals data by year-end to boost shares, says Piper Jaffray
SGEN Seattle Genetics
$117.00 /

-1.3 (-1.10%)

02/18/20 Barclays
Seattle Genetics downgraded to Equal Weight from Overweight at Barclays
02/18/20 Barclays
Seattle Genetics downgraded to Equal Weight from Overweight at Barclays
02/12/20 H.C. Wainwright
Seattle Genetics price target raised to $150 from $140 at H.C. Wainwright
02/11/20 Goldman Sachs
Goldman boosts Seattle Genetics target to $165, sees attractive setup
SNY Sanofi
$50.83 /

+0.07 (+0.14%)

02/11/20
Fly Intel: Top five analyst initiations
02/11/20 SVB Leerink
Sanofi initiated with a Market Perform at SVB Leerink
02/06/20 H.C. Wainwright
Principia Biopharma price target raised to $70 from $62 at H.C. Wainwright
01/26/20 Goldman Sachs
Denali Therapeutics upgraded to Buy from Neutral at Goldman Sachs
TAK Takeda Pharmaceutical
$18.78 /

+0.195 (+1.05%)

02/12/20 Wells Fargo
Fate Therapeutics price target raised to $34 from $24 at Wells Fargo
11/19/19 Needham
Phathom Pharmaceuticals initiated with a Buy at Needham
11/01/19 Cowen
Takeda Pharmaceutical initiated with a Market Perform at Cowen
09/24/19 Jefferies
Takeda Pharmaceutical initiated with a Buy at Jefferies
Conference/Events
The ASTCT and CIBMTR to hold a joint meeting » 04:55
02/21/20
02/21
04:55
02/21/20
04:55
ABBV

AbbVie

$94.26 /

+0.13 (+0.14%)

, ADPT

Adaptive Biotechnologies

$33.82 /

+0.28 (+0.83%)

, AMGN

Amgen

$222.18 /

-0.94 (-0.42%)

, ATNM

Actinium Pharmaceuticals

$0.25 /

+0.0011 (+0.44%)

, ATRA

Atara Biotherapeutics

$13.52 /

-1.23 (-8.34%)

, AZN

AstraZeneca

$48.97 /

-0.34 (-0.69%)

, BLUE

Bluebird Bio

$82.53 /

+1.98 (+2.46%)

, CDNA

CareDx

$28.12 /

-0.05 (-0.18%)

, CDTX

Cidara Therapeutics

$3.16 /

-0.01 (-0.32%)

, CELG

Bought by BMY

$0.00 /

+ (+0.00%)

, EQ

Equillium

$5.10 /

+0.04 (+0.79%)

, GMDA

Gamida Cell

$4.75 /

+ (+0.00%)

, GSK

GlaxoSmithKline

$42.76 /

+0.4688 (+1.11%)

, HUM

Humana

$371.55 /

-7.115 (-1.88%)

, INCY

Incyte

$82.77 /

+0.32 (+0.39%)

, JAZ

Jazz Technologies

$0.00 /

+ (+0.00%)

, KDMN

Kadmon

$5.05 /

-0.085 (-1.66%)

, MGTA

Magenta Therapeutics

$14.02 /

+0.91 (+6.94%)

, MRK

Merck

$82.48 /

+0.48 (+0.59%)

, NVS

Novartis

$96.31 /

-0.98 (-1.01%)

, PFE

Pfizer

$35.84 /

-0.39 (-1.08%)

, RCKT

Rocket Pharmaceuticals

$23.74 /

-0.26 (-1.08%)

, SGEN

Seattle Genetics

$118.30 /

-1.6 (-1.33%)

, SNY

Sanofi

$50.76 /

+0.06 (+0.12%)

, TAK

Takeda Pharmaceutical

$18.59 /

-0.43 (-2.26%)

American Society for…

American Society for Transplantation & Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) hold the 2020 TCT: Transplantation & Cellular Therapy Meeting will be held in Orlando on February 19-23.

ShowHide Related Items >><<
ABBV AbbVie
$94.26 /

+0.13 (+0.14%)

02/18/20 Cowen
AbbVie price target raised to $105 from $98 at Cowen
02/14/20 Piper Sandler
Piper says Ubrelvy prescription trajectory bodes well for Biohaven's rimegepant
02/11/20 SunTrust
Allergan price target raised to $202 from $194 at SunTrust
02/10/20 Mizuho
AbbVie price target raised to $104 from $96 at Mizuho
ADPT Adaptive Biotechnologies
$33.82 /

+0.28 (+0.83%)

01/09/20 JPMorgan
Danaher, Thermo named JPMorgan's top 2020 picks in Life Science Tools
11/13/19 JPMorgan
Adaptive Biotechnologies still has upside potential despite rally, says JPMorgan
07/23/19
Fly Intel: Top five analyst initiations
07/23/19 BTIG
Adaptive Biotechnologies initiated with a Buy at BTIG
AMGN Amgen
$222.18 /

-0.94 (-0.42%)

02/14/20
Vertex remains top large-cap biotech pick at Citi
02/06/20 Argus
Amgen trading at attractive valuation, says Argus
02/03/20 SunTrust
Amgen price target lowered to $254 from $265 at SunTrust
01/31/20
Fly Intel: Top five analyst downgrades
ATNM Actinium Pharmaceuticals
$0.25 /

+0.0011 (+0.44%)

08/08/19 William Blair
Actinium Pharmaceuticals initiated with an Outperform at William Blair
ATRA Atara Biotherapeutics
$13.52 /

-1.23 (-8.34%)

11/08/19 JPMorgan
Atara Biotherapeutics downgraded to on lack of catalysts at JPMorgan
11/08/19 JPMorgan
Atara Biotherapeutics downgraded to Neutral from Overweight at JPMorgan
10/25/19 Stifel
Stifel recommend buying into weakness on Atara Biotherapeutics CSO resignation
10/25/19 Mizuho
Mizuho says CSO Chris Haqq to remain on as Atara adviser
AZN AstraZeneca
$48.97 /

-0.34 (-0.69%)

01/27/20 William Blair
PhaseBio could see increase to PB2452 addressable market, says William Blair
01/22/20 Liberum
Sanofi downgraded to Hold from Buy at Liberum (earlier)
01/22/20 Oppenheimer
Amarin price target raised to $13 from $8 at Oppenheimer
01/13/20 Roth Capital
Amarin's Vascepa now the 'go-to' after competitor failures, says Roth Capital
BLUE Bluebird Bio
$82.53 /

+1.98 (+2.46%)

02/20/20 Oppenheimer
Bluebird Bio price target lowered to $128 from $135 at Oppenheimer
02/19/20 Raymond James
Bluebird Bio downgraded to Market Perform from Strong Buy at Raymond James
02/19/20 Piper Sandler
Bluebird pushed Biologics License Application to second half, says Piper Sandler
02/03/20 Evercore ISI
Bluebird Bio upgraded to Outperform on undervalued assets at Evercore ISI
CDNA CareDx
$28.12 /

-0.05 (-0.18%)

01/27/20 Piper Sandler
CareDx gained first private payer decision for AlloSure, says Piper Sandler
12/19/19 Craig-Hallum
Natera kidney test to be covered under Medicare in February, says Craig-Hallum
12/19/19 Piper Sandler
CareDx should be bought on weakness from Natera coverage, says Piper
11/01/19 Piper Sandler
CareDx continues to build 'moat around transplant,' says Piper Jaffray
CDTX Cidara Therapeutics
$3.16 /

-0.01 (-0.32%)

01/27/20 Cantor Fitzgerald
Street underappreciates Cidara's Cloudbreak AVCs, says Cantor Fitzgerald
12/04/19 WBB Securities
Cidara Therapeutics upgraded to Buy from Speculative Buy at WBB Securities
09/04/19 BTIG
Cidara Therapeutics price target lowered to $7 from $20 at BTIG
09/04/19
Cidara Therapeutics upgraded to Outperform after partnership at Wedbush
CELG Bought by BMY
$0.00 /

+ (+0.00%)

11/01/19 Standpoint Research
Celgene downgraded to Hold from Buy at Standpoint Research
11/01/19 Baird
Celgene downgraded to Neutral at Baird
11/01/19 Baird
Celgene downgraded d to Neutral from Outperform at Baird
09/23/19 Guggenheim
Agios Pharmaceuticals upgraded to Buy following selloff at Guggenheim
EQ Equillium
$5.10 /

+0.04 (+0.79%)

01/03/20 Stifel
Stifel says Incyte setback means Equillium may have most advanced aGVHD product
07/02/19 H.C. Wainwright
Equillium initiated with a Buy at H.C. Wainwright
02/22/19 SVB Leerink
Equillium initiated with an Outperform at SVB Leerink
GMDA Gamida Cell
$4.75 /

+ (+0.00%)

09/20/19 JMP Securities
Gamida Cell initiated with an Outperform at JMP Securities
GSK GlaxoSmithKline
$42.76 /

+0.4688 (+1.11%)

01/16/20 Barclays
GlaxoSmithKline downgraded to Underweight from Equal Weight at Barclays
12/16/19 Goldman Sachs
BioMarin, Regeneron among Goldman's six Healthcare 'laggards' for 2020
12/03/19 Morgan Stanley
Morgan Stanley sees high odds of Bluebird trading up after multiple myeloma data
12/02/19 SVB Leerink
GlaxoSmithKline initiated with an Outperform at SVB Leerink
HUM Humana
$371.55 /

-7.115 (-1.88%)

02/20/20 Stephens
Stephens watching near-term MCO stock reactions after Bloomberg's 'rough' debate
02/18/20 Deutsche Bank
Deutsche raises price targets in Managed Care on fading political risks
01/23/20 UBS
Humana price target raised to $406 from $321 at UBS
01/08/20 Credit Suisse
Humana price target raised to $400 from $378 at Credit Suisse
INCY Incyte
$82.77 /

+0.32 (+0.39%)

02/19/20 Piper Sandler
Incyte data on topical ruxolitinib 'impressive,' says Piper Sandler
02/19/20 Nomura Instinet
Incyte price target raised to $116 from $111 at Nomura Instinet
02/13/20 Piper Sandler
Piper Sandler says Incyte's Jakafi, 2020 launches are 'underappreciated'
02/04/20 BofA
Incyte reinstated with a Neutral at BofA
JAZ Jazz Technologies
$0.00 /

+ (+0.00%)

KDMN Kadmon
$5.05 /

-0.085 (-1.66%)

01/10/20 Nomura Instinet
Kadmon initiated with a Buy at Nomura Instinet
01/03/20 Cantor Fitzgerald
Incyte setback supports GVHD opportunity for Kadmon, says Cantor Fitzgerald
11/12/19 Cantor Fitzgerald
Kadmon price target raised to $10 from $8 at Cantor Fitzgerald
09/06/19 Cantor Fitzgerald
Cantor starts 'under-the-radar' Kadmon with Overweight rating
MGTA Magenta Therapeutics
$14.02 /

+0.91 (+6.94%)

01/15/20 BTIG
BTIG sees 'no real reason' for Magenta Therapeutics sell-off
12/06/19 BTIG
Magenta Therapeutics initiated with a Buy at BTIG
12/06/19 Goldman Sachs
Magenta Therapeutics assumed with a Neutral at Goldman Sachs
03/25/19 Goldman Sachs
Magenta Therapeutics downgraded to Neutral on valuation at Goldman Sachs
MRK Merck
$82.48 /

+0.48 (+0.59%)

02/19/20 Spin-Off Research
Merck initiated with a Buy at Spin-Off Research
02/14/20 SunTrust
Pfenex initiated with a Buy at SunTrust
02/06/20 RBC Capital
Merck price target lowered to $92 from $99 at RBC Capital
02/06/20 Maxim
Armata Pharmaceuticals initiated with a Buy at Maxim
NVS Novartis
$96.31 /

-0.98 (-1.01%)

02/17/20 Citi
Novartis downgraded to Neutral from Buy at Citi
02/03/20 Oppenheimer
Eyenovia downgraded to Perform from Outperform at Oppenheimer
01/06/20 JPMorgan
JPMorgan upgrades Sanofi to Overweight on 'unjustified' valuation gap
PFE Pfizer
$35.84 /

-0.39 (-1.08%)

02/12/20 Baird
Exact Sciences weakness would be buying opportunity, says Baird
02/11/20 Roth Capital
GlycoMimetics termination notice from Pfizer no surprise, says Roth Capital
02/06/20 Mizuho
Pfizer initiated with a Buy, $42 price target at Mizuho
02/05/20 Mizuho
Pfizer initiated with a Buy at Mizuho
RCKT Rocket Pharmaceuticals
$23.74 /

-0.26 (-1.08%)

12/09/19 Oppenheimer
Rocket Pharmaceuticals price target raised to $42 from $36 at Oppenheimer
12/06/19 Baird
Rocket Pharmaceuticals elevated to Fresh Pick, target raised to $41 at Baird
11/18/19 Piper Sandler
Rocket may be next leading lentiviral vector company, says Piper Jaffray
11/07/19 Piper Sandler
Rocket Pharmaceuticals data by year-end to boost shares, says Piper Jaffray
SGEN Seattle Genetics
$118.30 /

-1.6 (-1.33%)

02/18/20 Barclays
Seattle Genetics downgraded to Equal Weight from Overweight at Barclays
02/18/20 Barclays
Seattle Genetics downgraded to Equal Weight from Overweight at Barclays
02/12/20 H.C. Wainwright
Seattle Genetics price target raised to $150 from $140 at H.C. Wainwright
02/11/20 Goldman Sachs
Goldman boosts Seattle Genetics target to $165, sees attractive setup
SNY Sanofi
$50.76 /

+0.06 (+0.12%)

02/11/20
Fly Intel: Top five analyst initiations
02/11/20 SVB Leerink
Sanofi initiated with a Market Perform at SVB Leerink
02/06/20 H.C. Wainwright
Principia Biopharma price target raised to $70 from $62 at H.C. Wainwright
01/26/20 Goldman Sachs
Denali Therapeutics upgraded to Buy from Neutral at Goldman Sachs
TAK Takeda Pharmaceutical
$18.59 /

-0.43 (-2.26%)

02/12/20 Wells Fargo
Fate Therapeutics price target raised to $34 from $24 at Wells Fargo
11/19/19 Needham
Phathom Pharmaceuticals initiated with a Buy at Needham
11/01/19 Cowen
Takeda Pharmaceutical initiated with a Market Perform at Cowen
09/24/19 Jefferies
Takeda Pharmaceutical initiated with a Buy at Jefferies
Conference/Events
The ASTCT and CIBMTR to hold a joint meeting » 04:55
02/20/20
02/20
04:55
02/20/20
04:55
ABBV

AbbVie

$94.13 /

+0.53 (+0.57%)

, ADPT

Adaptive Biotechnologies

$33.54 /

+1.79 (+5.64%)

, AMGN

Amgen

$223.12 /

+1.38 (+0.62%)

, ATNM

Actinium Pharmaceuticals

$0.25 /

+0.0041 (+1.67%)

, ATRA

Atara Biotherapeutics

$14.75 /

+0.2 (+1.37%)

, AZN

AstraZeneca

$49.31 /

+0.14 (+0.28%)

, BLUE

Bluebird Bio

$80.55 /

-7.61 (-8.63%)

, CDNA

CareDx

$28.17 /

+1.02 (+3.76%)

, CDTX

Cidara Therapeutics

$3.17 /

+0.09 (+2.92%)

, CELG

Bought by BMY

$0.00 /

+ (+0.00%)

, EQ

Equillium

$5.06 /

+0.02 (+0.40%)

, GMDA

Gamida Cell

$4.75 /

-0.01 (-0.21%)

, GSK

GlaxoSmithKline

$43.49 /

-0.06 (-0.14%)

, HUM

Humana

$378.67 /

+6.41 (+1.72%)

, INCY

Incyte

$82.45 /

+3.2 (+4.04%)

, JAZ

Jazz Technologies

$0.00 /

+ (+0.00%)

, KDMN

Kadmon

$5.13 /

+0.285 (+5.88%)

, MGTA

Magenta Therapeutics

$13.11 /

+0.55 (+4.38%)

, MRK

Merck

$82.00 /

-0.46 (-0.56%)

, NVS

Novartis

$97.29 /

+0.08 (+0.08%)

, PFE

Pfizer

$36.23 /

-0.08 (-0.22%)

, RCKT

Rocket Pharmaceuticals

$24.00 /

-1.18 (-4.69%)

, SGEN

Seattle Genetics

$119.90 /

-0.09 (-0.08%)

, SNY

Sanofi

$50.70 /

-0.44 (-0.86%)

, TAK

Takeda Pharmaceutical

$19.02 /

-0.135 (-0.70%)

American Society for…

American Society for Transplantation & Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) hold the 2020 TCT: Transplantation & Cellular Therapy Meeting will be held in Orlando on February 19-23.

ShowHide Related Items >><<
ABBV AbbVie
$94.13 /

+0.53 (+0.57%)

02/18/20 Cowen
AbbVie price target raised to $105 from $98 at Cowen
02/14/20 Piper Sandler
Piper says Ubrelvy prescription trajectory bodes well for Biohaven's rimegepant
02/11/20 SunTrust
Allergan price target raised to $202 from $194 at SunTrust
02/10/20 Mizuho
AbbVie price target raised to $104 from $96 at Mizuho
ADPT Adaptive Biotechnologies
$33.54 /

+1.79 (+5.64%)

01/09/20 JPMorgan
Danaher, Thermo named JPMorgan's top 2020 picks in Life Science Tools
11/13/19 JPMorgan
Adaptive Biotechnologies still has upside potential despite rally, says JPMorgan
07/23/19
Fly Intel: Top five analyst initiations
07/23/19 BTIG
Adaptive Biotechnologies initiated with a Buy at BTIG
AMGN Amgen
$223.12 /

+1.38 (+0.62%)

02/14/20
Vertex remains top large-cap biotech pick at Citi
02/06/20 Argus
Amgen trading at attractive valuation, says Argus
02/03/20 SunTrust
Amgen price target lowered to $254 from $265 at SunTrust
01/31/20
Fly Intel: Top five analyst downgrades
ATNM Actinium Pharmaceuticals
$0.25 /

+0.0041 (+1.67%)

08/08/19 William Blair
Actinium Pharmaceuticals initiated with an Outperform at William Blair
ATRA Atara Biotherapeutics
$14.75 /

+0.2 (+1.37%)

11/08/19 JPMorgan
Atara Biotherapeutics downgraded to on lack of catalysts at JPMorgan
11/08/19 JPMorgan
Atara Biotherapeutics downgraded to Neutral from Overweight at JPMorgan
10/25/19 Stifel
Stifel recommend buying into weakness on Atara Biotherapeutics CSO resignation
10/25/19 Mizuho
Mizuho says CSO Chris Haqq to remain on as Atara adviser
AZN AstraZeneca
$49.31 /

+0.14 (+0.28%)

01/27/20 William Blair
PhaseBio could see increase to PB2452 addressable market, says William Blair
01/22/20 Liberum
Sanofi downgraded to Hold from Buy at Liberum (earlier)
01/22/20 Oppenheimer
Amarin price target raised to $13 from $8 at Oppenheimer
01/13/20 Roth Capital
Amarin's Vascepa now the 'go-to' after competitor failures, says Roth Capital
BLUE Bluebird Bio
$80.55 /

-7.61 (-8.63%)

02/19/20 Raymond James
Bluebird Bio downgraded to Market Perform from Strong Buy at Raymond James
02/19/20 Piper Sandler
Bluebird pushed Biologics License Application to second half, says Piper Sandler
02/03/20 Evercore ISI
Bluebird Bio upgraded to Outperform on undervalued assets at Evercore ISI
02/03/20 Evercore ISI
Evercore ISI downgrades Crispr Therapeutics, questions relative valuation
CDNA CareDx
$28.17 /

+1.02 (+3.76%)

01/27/20 Piper Sandler
CareDx gained first private payer decision for AlloSure, says Piper Sandler
12/19/19 Craig-Hallum
Natera kidney test to be covered under Medicare in February, says Craig-Hallum
12/19/19 Piper Sandler
CareDx should be bought on weakness from Natera coverage, says Piper
11/01/19 Piper Sandler
CareDx continues to build 'moat around transplant,' says Piper Jaffray
CDTX Cidara Therapeutics
$3.17 /

+0.09 (+2.92%)

01/27/20 Cantor Fitzgerald
Street underappreciates Cidara's Cloudbreak AVCs, says Cantor Fitzgerald
12/04/19 WBB Securities
Cidara Therapeutics upgraded to Buy from Speculative Buy at WBB Securities
09/04/19 BTIG
Cidara Therapeutics price target lowered to $7 from $20 at BTIG
09/04/19
Cidara Therapeutics upgraded to Outperform after partnership at Wedbush
CELG Bought by BMY
$0.00 /

+ (+0.00%)

11/01/19 Standpoint Research
Celgene downgraded to Hold from Buy at Standpoint Research
11/01/19 Baird
Celgene downgraded to Neutral at Baird
11/01/19 Baird
Celgene downgraded d to Neutral from Outperform at Baird
09/23/19 Guggenheim
Agios Pharmaceuticals upgraded to Buy following selloff at Guggenheim
EQ Equillium
$5.06 /

+0.02 (+0.40%)

01/03/20 Stifel
Stifel says Incyte setback means Equillium may have most advanced aGVHD product
07/02/19 H.C. Wainwright
Equillium initiated with a Buy at H.C. Wainwright
02/22/19 SVB Leerink
Equillium initiated with an Outperform at SVB Leerink
GMDA Gamida Cell
$4.75 /

-0.01 (-0.21%)

09/20/19 JMP Securities
Gamida Cell initiated with an Outperform at JMP Securities
GSK GlaxoSmithKline
$43.49 /

-0.06 (-0.14%)

01/16/20 Barclays
GlaxoSmithKline downgraded to Underweight from Equal Weight at Barclays
12/16/19 Goldman Sachs
BioMarin, Regeneron among Goldman's six Healthcare 'laggards' for 2020
12/03/19 Morgan Stanley
Morgan Stanley sees high odds of Bluebird trading up after multiple myeloma data
12/02/19 SVB Leerink
GlaxoSmithKline initiated with an Outperform at SVB Leerink
HUM Humana
$378.67 /

+6.41 (+1.72%)

02/18/20 Deutsche Bank
Deutsche raises price targets in Managed Care on fading political risks
01/23/20 UBS
Humana price target raised to $406 from $321 at UBS
01/08/20 Credit Suisse
Humana price target raised to $400 from $378 at Credit Suisse
01/03/20 JPMorgan
Humana price target raised to $448 from $437 at JPMorgan
INCY Incyte
$82.45 /

+3.2 (+4.04%)

02/19/20 Piper Sandler
Incyte data on topical ruxolitinib 'impressive,' says Piper Sandler
02/19/20 Nomura Instinet
Incyte price target raised to $116 from $111 at Nomura Instinet
02/13/20 Piper Sandler
Piper Sandler says Incyte's Jakafi, 2020 launches are 'underappreciated'
02/04/20 BofA
Incyte reinstated with a Neutral at BofA
JAZ Jazz Technologies
$0.00 /

+ (+0.00%)

KDMN Kadmon
$5.13 /

+0.285 (+5.88%)

01/10/20 Nomura Instinet
Kadmon initiated with a Buy at Nomura Instinet
01/03/20 Cantor Fitzgerald
Incyte setback supports GVHD opportunity for Kadmon, says Cantor Fitzgerald
11/12/19 Cantor Fitzgerald
Kadmon price target raised to $10 from $8 at Cantor Fitzgerald
09/06/19 Cantor Fitzgerald
Cantor starts 'under-the-radar' Kadmon with Overweight rating
MGTA Magenta Therapeutics
$13.11 /

+0.55 (+4.38%)

01/15/20 BTIG
BTIG sees 'no real reason' for Magenta Therapeutics sell-off
12/06/19 BTIG
Magenta Therapeutics initiated with a Buy at BTIG
12/06/19 Goldman Sachs
Magenta Therapeutics assumed with a Neutral at Goldman Sachs
03/25/19 Goldman Sachs
Magenta Therapeutics downgraded to Neutral on valuation at Goldman Sachs
MRK Merck
$82.00 /

-0.46 (-0.56%)

02/19/20 Spin-Off Research
Merck initiated with a Buy at Spin-Off Research
02/14/20 SunTrust
Pfenex initiated with a Buy at SunTrust
02/06/20 RBC Capital
Merck price target lowered to $92 from $99 at RBC Capital
02/06/20 Maxim
Armata Pharmaceuticals initiated with a Buy at Maxim
NVS Novartis
$97.29 /

+0.08 (+0.08%)

02/17/20 Citi
Novartis downgraded to Neutral from Buy at Citi
02/03/20 Oppenheimer
Eyenovia downgraded to Perform from Outperform at Oppenheimer
01/06/20 JPMorgan
JPMorgan upgrades Sanofi to Overweight on 'unjustified' valuation gap
PFE Pfizer
$36.23 /

-0.08 (-0.22%)

02/12/20 Baird
Exact Sciences weakness would be buying opportunity, says Baird
02/11/20 Roth Capital
GlycoMimetics termination notice from Pfizer no surprise, says Roth Capital
02/06/20 Mizuho
Pfizer initiated with a Buy, $42 price target at Mizuho
02/05/20 Mizuho
Pfizer initiated with a Buy at Mizuho
RCKT Rocket Pharmaceuticals
$24.00 /

-1.18 (-4.69%)

12/09/19 Oppenheimer
Rocket Pharmaceuticals price target raised to $42 from $36 at Oppenheimer
12/06/19 Baird
Rocket Pharmaceuticals elevated to Fresh Pick, target raised to $41 at Baird
11/18/19 Piper Sandler
Rocket may be next leading lentiviral vector company, says Piper Jaffray
11/07/19 Piper Sandler
Rocket Pharmaceuticals data by year-end to boost shares, says Piper Jaffray
SGEN Seattle Genetics
$119.90 /

-0.09 (-0.08%)

02/18/20 Barclays
Seattle Genetics downgraded to Equal Weight from Overweight at Barclays
02/18/20 Barclays
Seattle Genetics downgraded to Equal Weight from Overweight at Barclays
02/12/20 H.C. Wainwright
Seattle Genetics price target raised to $150 from $140 at H.C. Wainwright
02/11/20 Goldman Sachs
Goldman boosts Seattle Genetics target to $165, sees attractive setup
SNY Sanofi
$50.70 /

-0.44 (-0.86%)

02/11/20
Fly Intel: Top five analyst initiations
02/11/20 SVB Leerink
Sanofi initiated with a Market Perform at SVB Leerink
02/06/20 H.C. Wainwright
Principia Biopharma price target raised to $70 from $62 at H.C. Wainwright
01/26/20 Goldman Sachs
Denali Therapeutics upgraded to Buy from Neutral at Goldman Sachs
TAK Takeda Pharmaceutical
$19.02 /

-0.135 (-0.70%)

02/12/20 Wells Fargo
Fate Therapeutics price target raised to $34 from $24 at Wells Fargo
11/19/19 Needham
Phathom Pharmaceuticals initiated with a Buy at Needham
11/01/19 Cowen
Takeda Pharmaceutical initiated with a Market Perform at Cowen
09/24/19 Jefferies
Takeda Pharmaceutical initiated with a Buy at Jefferies
Conference/Events
The ASTCT and CIBMTR to hold a joint meeting » 08:09
02/19/20
02/19
08:09
02/19/20
08:09
ABBV

AbbVie

$93.60 /

-0.47 (-0.50%)

, ADPT

Adaptive Biotechnologies

$31.75 /

+0.29 (+0.92%)

, AMGN

Amgen

$221.74 /

-1.58 (-0.71%)

, ATNM

Actinium Pharmaceuticals

$0.25 /

-0.0132 (-5.09%)

, ATRA

Atara Biotherapeutics

$14.55 /

+0.3 (+2.11%)

, AZN

AstraZeneca

$49.17 /

+1.3 (+2.72%)

, BLUE

Bluebird Bio

$88.16 /

-0.98 (-1.10%)

, CDNA

CareDx

$27.15 /

+0.48 (+1.80%)

, CDTX

Cidara Therapeutics

$3.08 /

+0.1 (+3.36%)

, CELG

Bought by BMY

$0.00 /

+ (+0.00%)

, EQ

Equillium

$5.04 /

+0.06 (+1.20%)

, GMDA

Gamida Cell

$4.76 /

+0.035 (+0.74%)

, GSK

GlaxoSmithKline

$43.55 /

-0.19 (-0.43%)

, HUM

Humana

$372.26 /

-3.815 (-1.01%)

, INCY

Incyte

$79.25 /

+0.83 (+1.06%)

, JAZ

Jazz Technologies

$0.00 /

+ (+0.00%)

, KDMN

Kadmon

$4.85 /

+0.325 (+7.19%)

, MGTA

Magenta Therapeutics

$12.56 /

+0.2 (+1.62%)

, MRK

Merck

$82.46 /

-0.18 (-0.22%)

, NVS

Novartis

$97.21 /

-0.465 (-0.48%)

, PFE

Pfizer

$36.31 /

-0.18 (-0.49%)

, RCKT

Rocket Pharmaceuticals

$25.18 /

+1.18 (+4.92%)

, SGEN

Seattle Genetics

$119.99 /

+1.9 (+1.61%)

, SNY

Sanofi

$51.14 /

+1.21 (+2.42%)

, TAK

Takeda Pharmaceutical

$19.15 /

-0.29 (-1.49%)

American Society for…

American Society for Transplantation & Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) hold the 2020 TCT: Transplantation & Cellular Therapy Meeting will be held in Orlando on February 19-23.

ShowHide Related Items >><<
ABBV AbbVie
$93.60 /

-0.47 (-0.50%)

02/18/20 Cowen
AbbVie price target raised to $105 from $98 at Cowen
02/14/20 Piper Sandler
Piper says Ubrelvy prescription trajectory bodes well for Biohaven's rimegepant
02/11/20 SunTrust
Allergan price target raised to $202 from $194 at SunTrust
02/10/20 Mizuho
AbbVie price target raised to $104 from $96 at Mizuho
ADPT Adaptive Biotechnologies
$31.75 /

+0.29 (+0.92%)

01/09/20 JPMorgan
Danaher, Thermo named JPMorgan's top 2020 picks in Life Science Tools
11/13/19 JPMorgan
Adaptive Biotechnologies still has upside potential despite rally, says JPMorgan
07/23/19
Fly Intel: Top five analyst initiations
07/23/19 BTIG
Adaptive Biotechnologies initiated with a Buy at BTIG
AMGN Amgen
$221.74 /

-1.58 (-0.71%)

02/14/20
Vertex remains top large-cap biotech pick at Citi
02/06/20 Argus
Amgen trading at attractive valuation, says Argus
02/03/20 SunTrust
Amgen price target lowered to $254 from $265 at SunTrust
01/31/20
Fly Intel: Top five analyst downgrades
ATNM Actinium Pharmaceuticals
$0.25 /

-0.0132 (-5.09%)

08/08/19 William Blair
Actinium Pharmaceuticals initiated with an Outperform at William Blair
ATRA Atara Biotherapeutics
$14.55 /

+0.3 (+2.11%)

11/08/19 JPMorgan
Atara Biotherapeutics downgraded to on lack of catalysts at JPMorgan
11/08/19 JPMorgan
Atara Biotherapeutics downgraded to Neutral from Overweight at JPMorgan
10/25/19 Stifel
Stifel recommend buying into weakness on Atara Biotherapeutics CSO resignation
10/25/19 Mizuho
Mizuho says CSO Chris Haqq to remain on as Atara adviser
AZN AstraZeneca
$49.17 /

+1.3 (+2.72%)

01/27/20 William Blair
PhaseBio could see increase to PB2452 addressable market, says William Blair
01/22/20 Liberum
Sanofi downgraded to Hold from Buy at Liberum (earlier)
01/22/20 Oppenheimer
Amarin price target raised to $13 from $8 at Oppenheimer
01/13/20 Roth Capital
Amarin's Vascepa now the 'go-to' after competitor failures, says Roth Capital
BLUE Bluebird Bio
$88.16 /

-0.98 (-1.10%)

02/19/20 Piper Sandler
Bluebird pushed Biologics License Application to second half, says Piper Sandler
02/03/20 Evercore ISI
Bluebird Bio upgraded to Outperform on undervalued assets at Evercore ISI
02/03/20 Evercore ISI
Evercore ISI downgrades Crispr Therapeutics, questions relative valuation
02/03/20 Evercore ISI
Bluebird Bio upgraded to Outperform from In Line at Evercore ISI
CDNA CareDx
$27.15 /

+0.48 (+1.80%)

01/27/20 Piper Sandler
CareDx gained first private payer decision for AlloSure, says Piper Sandler
12/19/19 Craig-Hallum
Natera kidney test to be covered under Medicare in February, says Craig-Hallum
12/19/19 Piper Sandler
CareDx should be bought on weakness from Natera coverage, says Piper
11/01/19 Piper Sandler
CareDx continues to build 'moat around transplant,' says Piper Jaffray
CDTX Cidara Therapeutics
$3.08 /

+0.1 (+3.36%)

01/27/20 Cantor Fitzgerald
Street underappreciates Cidara's Cloudbreak AVCs, says Cantor Fitzgerald
12/04/19 WBB Securities
Cidara Therapeutics upgraded to Buy from Speculative Buy at WBB Securities
09/04/19 BTIG
Cidara Therapeutics price target lowered to $7 from $20 at BTIG
09/04/19
Cidara Therapeutics upgraded to Outperform after partnership at Wedbush
CELG Bought by BMY
$0.00 /

+ (+0.00%)

11/01/19 Standpoint Research
Celgene downgraded to Hold from Buy at Standpoint Research
11/01/19 Baird
Celgene downgraded to Neutral at Baird
11/01/19 Baird
Celgene downgraded d to Neutral from Outperform at Baird
09/23/19 Guggenheim
Agios Pharmaceuticals upgraded to Buy following selloff at Guggenheim
EQ Equillium
$5.04 /

+0.06 (+1.20%)

01/03/20 Stifel
Stifel says Incyte setback means Equillium may have most advanced aGVHD product
07/02/19 H.C. Wainwright
Equillium initiated with a Buy at H.C. Wainwright
02/22/19 SVB Leerink
Equillium initiated with an Outperform at SVB Leerink
GMDA Gamida Cell
$4.76 /

+0.035 (+0.74%)

09/20/19 JMP Securities
Gamida Cell initiated with an Outperform at JMP Securities
GSK GlaxoSmithKline
$43.55 /

-0.19 (-0.43%)

01/16/20 Barclays
GlaxoSmithKline downgraded to Underweight from Equal Weight at Barclays
12/16/19 Goldman Sachs
BioMarin, Regeneron among Goldman's six Healthcare 'laggards' for 2020
12/03/19 Morgan Stanley
Morgan Stanley sees high odds of Bluebird trading up after multiple myeloma data
12/02/19 SVB Leerink
GlaxoSmithKline initiated with an Outperform at SVB Leerink
HUM Humana
$372.26 /

-3.815 (-1.01%)

02/18/20 Deutsche Bank
Deutsche raises price targets in Managed Care on fading political risks
01/23/20 UBS
Humana price target raised to $406 from $321 at UBS
01/08/20 Credit Suisse
Humana price target raised to $400 from $378 at Credit Suisse
01/03/20 JPMorgan
Humana price target raised to $448 from $437 at JPMorgan
INCY Incyte
$79.25 /

+0.83 (+1.06%)

02/19/20 Nomura Instinet
Incyte price target raised to $116 from $111 at Nomura Instinet
02/13/20 Piper Sandler
Piper Sandler says Incyte's Jakafi, 2020 launches are 'underappreciated'
02/04/20 BofA
Incyte reinstated with a Neutral at BofA
02/04/20 BofA
Incyte reinstated with a Neutral at BofA
JAZ Jazz Technologies
$0.00 /

+ (+0.00%)

KDMN Kadmon
$4.85 /

+0.325 (+7.19%)

01/10/20 Nomura Instinet
Kadmon initiated with a Buy at Nomura Instinet
01/03/20 Cantor Fitzgerald
Incyte setback supports GVHD opportunity for Kadmon, says Cantor Fitzgerald
11/12/19 Cantor Fitzgerald
Kadmon price target raised to $10 from $8 at Cantor Fitzgerald
09/06/19 Cantor Fitzgerald
Cantor starts 'under-the-radar' Kadmon with Overweight rating
MGTA Magenta Therapeutics
$12.56 /

+0.2 (+1.62%)

01/15/20 BTIG
BTIG sees 'no real reason' for Magenta Therapeutics sell-off
12/06/19 BTIG
Magenta Therapeutics initiated with a Buy at BTIG
12/06/19 Goldman Sachs
Magenta Therapeutics assumed with a Neutral at Goldman Sachs
03/25/19 Goldman Sachs
Magenta Therapeutics downgraded to Neutral on valuation at Goldman Sachs
MRK Merck
$82.46 /

-0.18 (-0.22%)

02/14/20 SunTrust
Pfenex initiated with a Buy at SunTrust
02/06/20 RBC Capital
Merck price target lowered to $92 from $99 at RBC Capital
02/06/20 Maxim
Armata Pharmaceuticals initiated with a Buy at Maxim
01/07/20
Fly Intel: Top five analyst initiations
NVS Novartis
$97.21 /

-0.465 (-0.48%)

02/17/20 Citi
Novartis downgraded to Neutral from Buy at Citi
02/03/20 Oppenheimer
Eyenovia downgraded to Perform from Outperform at Oppenheimer
01/06/20 JPMorgan
JPMorgan upgrades Sanofi to Overweight on 'unjustified' valuation gap
PFE Pfizer
$36.31 /

-0.18 (-0.49%)

02/12/20 Baird
Exact Sciences weakness would be buying opportunity, says Baird
02/11/20 Roth Capital
GlycoMimetics termination notice from Pfizer no surprise, says Roth Capital
02/06/20 Mizuho
Pfizer initiated with a Buy, $42 price target at Mizuho
02/05/20 Mizuho
Pfizer initiated with a Buy at Mizuho
RCKT Rocket Pharmaceuticals
$25.18 /

+1.18 (+4.92%)

12/09/19 Oppenheimer
Rocket Pharmaceuticals price target raised to $42 from $36 at Oppenheimer
12/06/19 Baird
Rocket Pharmaceuticals elevated to Fresh Pick, target raised to $41 at Baird
11/18/19 Piper Sandler
Rocket may be next leading lentiviral vector company, says Piper Jaffray
11/07/19 Piper Sandler
Rocket Pharmaceuticals data by year-end to boost shares, says Piper Jaffray
SGEN Seattle Genetics
$119.99 /

+1.9 (+1.61%)

02/18/20 Barclays
Seattle Genetics downgraded to Equal Weight from Overweight at Barclays
02/18/20 Barclays
Seattle Genetics downgraded to Equal Weight from Overweight at Barclays
02/12/20 H.C. Wainwright
Seattle Genetics price target raised to $150 from $140 at H.C. Wainwright
02/11/20 Goldman Sachs
Goldman boosts Seattle Genetics target to $165, sees attractive setup
SNY Sanofi
$51.14 /

+1.21 (+2.42%)

02/11/20
Fly Intel: Top five analyst initiations
02/11/20 SVB Leerink
Sanofi initiated with a Market Perform at SVB Leerink
02/06/20 H.C. Wainwright
Principia Biopharma price target raised to $70 from $62 at H.C. Wainwright
01/26/20 Goldman Sachs
Denali Therapeutics upgraded to Buy from Neutral at Goldman Sachs
TAK Takeda Pharmaceutical
$19.15 /

-0.29 (-1.49%)

02/12/20 Wells Fargo
Fate Therapeutics price target raised to $34 from $24 at Wells Fargo
11/19/19 Needham
Phathom Pharmaceuticals initiated with a Buy at Needham
11/01/19 Cowen
Takeda Pharmaceutical initiated with a Market Perform at Cowen
09/24/19 Jefferies
Takeda Pharmaceutical initiated with a Buy at Jefferies
Hot Stocks
Amgen Canada gets approval of MA transfer of Otezla for psoriasis treatment » 11:44
02/12/20
02/12
11:44
02/12/20
11:44
AMGN

Amgen

$226.12 /

-2.82 (-1.23%)

, CELG

Bought by BMY

$0.00 /

+ (+0.00%)

Amgen Canada announced…

Amgen Canada announced Health Canada's approval of the Marketing Authorization transfer of Otezla, apremilast, from Celgene to Amgen Canada. This transfer is in line with Amgen Inc.'s previously announced acquisition of the worldwide rights to OTEZLA completed in November 2019. "We are pleased that Health Canada has granted approval for Amgen to market OTEZLA in Canada and we are proud to offer this treatment option to those who need it most, including those living with debilitating, inflammatory conditions," says Brian Heath, vice president and general manager at Amgen Canada. "OTEZLA represents a unique opportunity to build on our long-standing commitment in psoriasis and inflammation and enhances our ability to support both patients and their physicians."

ShowHide Related Items >><<
AMGN Amgen
$226.12 /

-2.82 (-1.23%)

02/06/20 Argus
Amgen trading at attractive valuation, says Argus
02/03/20 SunTrust
Amgen price target lowered to $254 from $265 at SunTrust
01/31/20
Fly Intel: Top five analyst downgrades
01/31/20 Morgan Stanley
Amgen guidance appears conservative, says Morgan Stanley
CELG Bought by BMY
$0.00 /

+ (+0.00%)

11/01/19 Standpoint Research
Celgene downgraded to Hold from Buy at Standpoint Research
11/01/19 Baird
Celgene downgraded to Neutral at Baird
11/01/19 Baird
Celgene downgraded d to Neutral from Outperform at Baird
09/23/19 Guggenheim
Agios Pharmaceuticals upgraded to Buy following selloff at Guggenheim
Earnings
Fly Intel: What to watch in large-cap biotech earnings reports » 15:09
01/30/20
01/30
15:09
01/30/20
15:09
AMGN

Amgen

$225.05 /

-2.11 (-0.93%)

, BIIB

Biogen

$277.45 /

-5.08 (-1.80%)

, GILD

Gilead

$63.82 /

-0.48 (-0.75%)

, CELG

Bought by BMY

$0.00 /

+ (+0.00%)

The earnings season for…

The earnings season for large-cap biotech companies is here with Biogen (BIIB) having reported Thursday morning and Amgen (AMGN) set to report after the close. Gilead Sciences (GILD) and Celgene parent Bristol-Myers (BMY) are set to report quarterly results in early February. 1. BIOGEN REPORTS: Biogen shares are lower on Thursday after reporting fourth-quarter results slightly ahead of estimates, and guidance for the year 2020 that was basically in line with forecasts. Revenue from Spinraza, which treats spinal muscular atrophy, totaled $543M in Q4, down about 1% from the third quarter. The company is however optimistic about opportunities, especially in developing treatments for Alzheimer's disease, ALS, stroke, and lupus, according to a statement earlier form its CEO Michel Vounatsos. Shares of Biogen are down approximately 15% since the company's Q4 report in 2019. 2. AMGEN IS NEXT: Amgen, which makes blockbuster rheumatoid arthritis treatment Enbrel, has struggled since the beginning or 2020, with shares down around 8%. The company completed its acquisition of plaque psoriasis and psoriatic arthritis treatment Otzela from Celgene in connection with its previously announced merger with Bristol-Myers Squibb which was completed on Nov. 20. Cantor Fitzgerald analyst Alethia Young reiterates an Overweight rating on Amgen with a $255 price target. Although Amgen had a strong 2019 stock performance, the company remains well-positioned to outperform in 2020 as well, Young told investors in a research note. 3. CORONAVIRUS AND GILEAD'S EBOLA TREATMENT: Gilead, down around 8% since this time last year, will report Q4 earnings early next week. Gilead, which focuses on antiviral drugs to treat HIV and other diseases, is in discussions with medical experts in the United States and China "regarding the ongoing Wuhan coronavirus outbreak and the potential use of remdesivir as an investigational treatment, the company confirmed in a Thursday email to Bloomberg Law. "Plans for next steps, including engagement with regulatory authorities, are ongoing," said the drug company according to Bloomberg. Remdesivir was originally developed by Gilead as a treatment for Ebola virus and Marburg virus infections. 4. BRISTOL MEYERS BULL RUN: Bristol Meyers, which reports Q4 results on February 6 has been on a tear since late July with its share price up around 60%. The drug giant, which received approval from the FTC for its Celgene acquisition plans to o launch eight drugs in the next 12 to 18 months, the drug maker's COO told Business Insider. At the beginning of January Citi analyst, Andrew Baum resumed coverage of Bristol-Myers and upgraded the stock to Buy from Neutral with a price target of $73, up from $57 previously. The acquisition of Celgene lowers the company's reliance on Opdivo and brings pipeline optionality, said Baum, who also believes the market is underappreciating the newly-merged company's near-term cash generation and pipeline potential.

ShowHide Related Items >><<
AMGN Amgen
$225.05 /

-2.11 (-0.93%)

01/23/20 Citi
Amgen price target raised to $275 from $245 at Citi
01/21/20 Piper Sandler
Piper says Cytokinetics shares could be propelled higher by omecamtiv data
01/21/20 Evercore ISI
Amgen upgraded to Outperform on earnings power at Evercore ISI
01/21/20 Evercore ISI
Amgen upgraded to Outperform from In Line at Evercore ISI
BIIB Biogen
$277.45 /

-5.08 (-1.80%)

01/27/20
Fly Intel: Top five analyst upgrades
01/27/20 Canaccord
Canaccord upgrades Biogen to Buy on 'decent shot' of Alzheimer's approval
01/27/20 Canaccord
Biogen upgraded to Buy from Hold at Canaccord
01/02/20 Piper Sandler
Biogen MS drug price increases 'business as usual,' says Piper Jaffray
GILD Gilead
$63.82 /

-0.48 (-0.75%)

01/29/20 Piper Sandler
Piper keeps Neutral rating on Spring Bank after inarigivir discontinued
01/21/20 Guggenheim
Gilead downgraded to Neutral from Buy at Guggenheim
01/02/20 Piper Sandler
Gilead HIV drug price hikes 'appear reasonable,' says Piper Jaffray
12/18/19 JPMorgan
BioMarin, Vertex among JPMorgan's top Biotech picks for 2020
CELG Bought by BMY
$0.00 /

+ (+0.00%)

11/01/19 Standpoint Research
Celgene downgraded to Hold from Buy at Standpoint Research
11/01/19 Baird
Celgene downgraded to Neutral at Baird
11/01/19 Baird
Celgene downgraded d to Neutral from Outperform at Baird
09/23/19 Guggenheim
Agios Pharmaceuticals upgraded to Buy following selloff at Guggenheim
Hot Stocks
Forma announces milestone for CC-95775 assets licensed to Bristol-Myers » 07:10
01/30/20
01/30
07:10
01/30/20
07:10
BMY

Bristol-Myers

$64.14 /

-0.68 (-1.05%)

, CELG

Bought by BMY

$0.00 /

+ (+0.00%)

Forma Therapeutics…

Forma Therapeutics announced the achievement of clinical development milestones for two of its exclusively-licensed, clinical-stage products to Boehringer Ingelheim, or BI, and Bristol-Myers. Bristol Meyers initiated an open-label, Phase 1B dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of CC-95775 in patients with advanced or unresectable solid tumors. CC-95775 is a pan-BET bromodomain inhibitor that was discovered under a partnership between Forma and Celgene and exclusively licensed to Celgene in 2018. BMS is responsible for further development, and Forma is eligible to receive potential milestone payments plus royalties for this and another asset based upon development, regulatory and sales objectives. Forma recently presented data from a Phase 1 study of CC-95775 as a single agent in patients with relapsed or refractory hematologic malignancies at the 2019 American Society of Hematology annual meeting.

ShowHide Related Items >><<
BMY Bristol-Myers
$64.14 /

-0.68 (-1.05%)

01/10/20 Goldman Sachs
Goldman keeps Sell on Nektar despite amended Bristol-Myers Squibb agreement
01/10/20 Piper Sandler
Nektar update with Bristol-Myers 'positive all around,' says Piper Sandler
01/10/20 H.C. Wainwright
Amended Nektar, Bristol pact reflects bempeg limitations, says H.C. Wainwright
01/06/20 Citi
Bristol-Myers upgraded to Buy from Neutral on resumption at Citi
CELG Bought by BMY
$0.00 /

+ (+0.00%)

11/01/19 Standpoint Research
Celgene downgraded to Hold from Buy at Standpoint Research
11/01/19 Baird
Celgene downgraded to Neutral at Baird
11/01/19 Baird
Celgene downgraded d to Neutral from Outperform at Baird
09/23/19 Guggenheim
Agios Pharmaceuticals upgraded to Buy following selloff at Guggenheim
Conference/Events
Drug Information Association to hold a conference » 06:55
01/29/20
01/29
06:55
01/29/20
06:55
ABBV

AbbVie

$83.76 /

-0.27 (-0.32%)

, ALLO

Allogene Therapeutics

$22.62 /

-0.005 (-0.02%)

, ALXN

Alexion

$107.00 /

+1.62 (+1.54%)

, BMY

Bristol-Myers

$64.82 /

+1.11 (+1.74%)

, CELG

Bought by BMY

$0.00 /

+ (+0.00%)

, CRBP

Corbus Pharmaceuticals

$6.66 /

+0.05 (+0.76%)

, ESALY

Eisai

$0.00 /

+ (+0.00%)

, EXPO

Exponent

$73.59 /

+0.38 (+0.52%)

, GSK

GlaxoSmithKline

$46.80 /

+0.32 (+0.69%)

, HALO

Halozyme

$19.41 /

+0.24 (+1.25%)

, IQV

Iqvia

$158.66 /

+1.51 (+0.96%)

, LLY

Eli Lilly

$139.20 /

+0.82 (+0.59%)

, PFE

Pfizer

$38.10 /

-2.06 (-5.13%)

Pharmacovigilance &…

Pharmacovigilance & Risk Management Strategies Conference will be held in Washington, D.C. on January 27-29.

ShowHide Related Items >><<
ABBV AbbVie
$83.76 /

-0.27 (-0.32%)

01/22/20 Wells Fargo
Allergan downgraded to Equal Weight from Overweight at Wells Fargo
01/07/20
Fly Intel: Top five analyst initiations
01/06/20 RBC Capital
AbbVie initiated with a Sector Perform at RBC Capital
12/26/19 Cowen
AbbVie price target raised to $98 from $90 at Cowen
ALLO Allogene Therapeutics
$22.62 /

-0.005 (-0.02%)

12/18/19 JMP Securities
Allogene Therapeutics initiated with an Outperform at JMP Securities
11/04/19
Fly Intel: Top five analyst initiations
11/04/19 Canaccord
Allogene Therapeutics initiated with a Buy at Canaccord
08/09/19 BTIG
Allogene Therapeutics initiated with a Buy at BTIG
ALXN Alexion
$107.00 /

+1.62 (+1.54%)

01/15/20 Raymond James
Alexion price target raised to $162 from $161 at Raymond James
01/13/20 Piper Sandler
Alexion a large cap top pick for 2020, says Piper Sandler
01/07/20 JPMorgan
Alexion competitor data 'good,' but impact likely incremental, says JPMorgan
01/07/20 Citi
Apellis price target raised to $80 from $37 at Citi
BMY Bristol-Myers
$64.82 /

+1.11 (+1.74%)

01/10/20 Goldman Sachs
Goldman keeps Sell on Nektar despite amended Bristol-Myers Squibb agreement
01/10/20 Piper Sandler
Nektar update with Bristol-Myers 'positive all around,' says Piper Sandler
01/10/20 H.C. Wainwright
Amended Nektar, Bristol pact reflects bempeg limitations, says H.C. Wainwright
01/06/20 Citi
Bristol-Myers upgraded to Buy from Neutral on resumption at Citi
CELG Bought by BMY
$0.00 /

+ (+0.00%)

11/01/19 Standpoint Research
Celgene downgraded to Hold from Buy at Standpoint Research
11/01/19 Baird
Celgene downgraded to Neutral at Baird
11/01/19 Baird
Celgene downgraded d to Neutral from Outperform at Baird
09/23/19 Guggenheim
Agios Pharmaceuticals upgraded to Buy following selloff at Guggenheim
CRBP Corbus Pharmaceuticals
$6.66 /

+0.05 (+0.76%)

04/22/19 JMP Securities
Corbus Phase 3 scleroderma study change a 'surprise move,' says JMP Securities
04/05/19
Fly Intel: Top five analyst initiations
04/05/19 Jefferies
Corbus Pharmaceuticals initiated with a Buy at Jefferies
03/19/19 Oppenheimer
Corbus jumps over 10% after Oppenheimer starts with $28 price target
ESALY Eisai
$0.00 /

+ (+0.00%)

10/24/19 Nomura Instinet
Eisai upgraded to Buy from Neutral at Nomura Instinet
09/24/19 Jefferies
Eisai initiated with a Buy at Jefferies
09/17/19 Daiwa
Eisai downgraded to Sell from Neutral at Daiwa
08/05/19 Citi
Eisai upgraded to Neutral from Sell at Citi
EXPO Exponent
$73.59 /

+0.38 (+0.52%)

12/18/19
Exponent management to meet with Sidoti
09/20/19 SunTrust
Exponent price target raised to $81 from $70 at SunTrust
08/29/19
Fly Intel: Top five analyst initiations
08/28/19 DA Davidson
Exponent initiated with a Neutral at DA Davidson
GSK GlaxoSmithKline
$46.80 /

+0.32 (+0.69%)

01/16/20 Barclays
GlaxoSmithKline downgraded to Underweight from Equal Weight at Barclays
12/16/19 Goldman Sachs
BioMarin, Regeneron among Goldman's six Healthcare 'laggards' for 2020
12/03/19 Morgan Stanley
Morgan Stanley sees high odds of Bluebird trading up after multiple myeloma data
12/02/19 SVB Leerink
GlaxoSmithKline initiated with an Outperform at SVB Leerink
HALO Halozyme
$19.41 /

+0.24 (+1.25%)

01/27/20 Cantor Fitzgerald
Halozyme price target raised to $35 from $27 at Cantor Fitzgerald
01/09/20 BMO Capital
Halozyme upgraded to Outperform from Market Perform at BMO Capital
01/08/20 Goldman Sachs
Halozyme initiated with a Buy at Goldman Sachs
11/05/19 Barclays
Halozyme upgraded to Equal Weight after HALO-301 failure at Barclays
IQV Iqvia
$158.66 /

+1.51 (+0.96%)

01/13/20 Morgan Stanley
Veeva upgraded to Overweight following underperformance at Morgan Stanley
01/07/20 Wells Fargo
Wells Fargo initiates Life Science Tools, Services, Diagnostics Sector
01/07/20 Wells Fargo
Iqvia initiated with an Overweight at Wells Fargo
01/06/20 Citi
Iqvia initiated with a Buy at Citi
LLY Eli Lilly
$139.20 /

+0.82 (+0.59%)

01/23/20 H.C. Wainwright
Dermira downgraded to Neutral from Buy at H.C. Wainwright
01/13/20 Piper Sandler
Partnership termination not a negative for NextCure N318, says Piper Sandler
01/08/20 Piper Sandler
Eli Lilly still has edge over Blueprint in RET+ lung cancer, says Piper Sandler
12/30/19 Argus
Eli Lilly price target raised to $165 from $145 at Argus
PFE Pfizer
$38.10 /

-2.06 (-5.13%)

01/29/20 Cantor Fitzgerald
Pfizer growth prospect concerns overblown, says Cantor Fitzgerald
01/14/20 Ladenburg
Axsome Therapeutics price target raised to $165 from $139 at Ladenburg
01/13/20 Guggenheim
Zymeworks named Best Idea at Guggenheim after Pfizer agreement

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.